Screener
Cullinan Therapeutics, Inc. CGEM Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Prepaid expenses and other assets | 1,426 | 5,259 |
| Accounts payable | 2,883 | 779 |
| Accrued expenses and other liabilities | (98) | (3,643) |
| Net cash used in operating activities | (84,264) | (100,764) |
| Investing activities: | ||
| Maturities of marketable securities | 107,799 | 294,572 |
| Purchases of marketable securities | (34,707) | (204,366) |
| Net cash provided by investing activities | 73,092 | 90,206 |
Item 1. Financial Statements.
FAQ
- What is Cullinan Therapeutics, Inc.'s operating cash flow?
- Cullinan Therapeutics, Inc. (CGEM) reported operating cash flow of -$38.22M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Cullinan Therapeutics, Inc.'s operating cash flow increased by 33.7% year-over-year, from -$57.61M to -$38.22M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s operating cash flow has grown at a 41.8% compound annual growth rate (CAGR), from -$43.43M to -$175.75M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Cullinan Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude